Asset

Ruxolitinib Phosphate

Incyte Corp. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (4)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00778700phase2completed2008-10-282009-06-26Incyte CorporationA Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
NCT03257644phase1completed2017-09-212020-10-07Incyte CorporationA Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
NCT02553330phase2terminated2015-11-182017-10-03Incyte CorporationA Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
NCT00820950phase2completed2007-05-312009-01-31Incyte CorporationA Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

FDA applications (3)

ApplicationTypeApplicant
NDA 202192NDAINCYTE CORP
NDA 215309NDAINCYTE CORP
NDA 217180NDAINCYTE CORP

Marketed products (11)

  • JAKAFI
  • JAKAFI
  • JAKAFI
  • JAKAFI
  • JAKAFI
  • JAKAFI XR
  • JAKAFI XR
  • JAKAFI XR
  • JAKAFI XR
  • JAKAFI XR
  • OPZELURA